JLL Partners Forms New Pharma Company With DSM and Acquires Patheon

Skadden is representing JLL Partners in a series of transactions aggregating $2.6 billion with Royal DSM, a Dutch chemicals and nutrition company, and Patheon Inc., a pharmaceutical manufacturing and development company, announced on November 19. Patheon, which is currently 56 percent owned by JLL, will be combined with a DSM subsidiary to form a new company that will be 51 percent owned by JLL and 49 percent owned by DSM.